<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04835792</url>
  </required_header>
  <id_info>
    <org_study_id>FP-LD-001</org_study_id>
    <nct_id>NCT04835792</nct_id>
  </id_info>
  <brief_title>Biomarker Study of Previously Treated Lyme Disease Volunteers in Comparison to Healthy Volunteers</brief_title>
  <official_title>Biomarker Study to Evaluate Participants With Previously Treated Lyme Disease in Comparison to Healthy Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>FlightPath Biosciences, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>FlightPath Biosciences, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Non-interventional study evaluating stool and blood samples collected from individuals&#xD;
      previously treated with Lyme disease versus healthy volunteers&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 21, 2021</start_date>
  <completion_date type="Anticipated">September 30, 2021</completion_date>
  <primary_completion_date type="Anticipated">September 30, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>• To evaluate and compare the microbiome of normal participants and participants with previously treated Lyme Disease</measure>
    <time_frame>30 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>• To evaluate and compare the transcriptome of normal participants and participants with previously treated Lyme Disease</measure>
    <time_frame>30 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>• To evaluate and compare the metabolome of normal participants and participants with previously treated Lyme Disease</measure>
    <time_frame>30 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>• Evaluation of symptoms and prior medications/treatments of normal participants and participants with previously treated Lyme Disease</measure>
    <time_frame>30 days</time_frame>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">1000</enrollment>
  <condition>Lyme Disease</condition>
  <arm_group>
    <arm_group_label>Previously Treated for Lyme Disease</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Healthy Volunteers</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Stool and blood collection</intervention_name>
    <description>One-time stool and blood collection</description>
    <arm_group_label>Healthy Volunteers</arm_group_label>
    <arm_group_label>Previously Treated for Lyme Disease</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Previously treated Lyme disease volunteers and healthy volunteers&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Males and females ≥18 years of age.&#xD;
&#xD;
          2. Able to read, understand, and provide signed informed consent.&#xD;
&#xD;
          3. Willing to provide blood and stool samples.&#xD;
&#xD;
          4. Able to communicate adequately and to comply with the requirements for the entire&#xD;
             study.&#xD;
&#xD;
          5. Must be willing to discontinue antibiotics 2 weeks prior to sample collection.&#xD;
&#xD;
          6. If participating in the previously treated Lyme Disease arm, the participants must&#xD;
             meet the following criteria: 1) Diagnosis of prior Lyme Disease supported by either an&#xD;
             erythema migrans rash (either classic &quot;bull's eye&quot; or irregular) OR a CDC-positive&#xD;
             Western blot, 2) previously treated with antibiotics for Lyme Disease, 3) remains ill&#xD;
             six months or more after receiving preliminary treatment with antibiotics for Lyme&#xD;
             disease (e.g., fatigue, musculoskeletal pain, or neurocognitive symptoms).&#xD;
&#xD;
          7. If participating in the healthy volunteer arm, the participants must meet the&#xD;
             following criteria: 1) must not have had a Lyme Disease diagnosis, 2) in generally&#xD;
             good health&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        1. Unwilling or unable to comply with the protocol (e.g., scheduled visits, laboratory&#xD;
        tests, other study procedures, and study restrictions).&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Matt Tindall</last_name>
    <phone>415-530-1828</phone>
    <email>matt@flightpath.bio</email>
  </overall_contact>
  <location>
    <facility>
      <name>Dr. Curtis Scribner</name>
      <address>
        <city>Berkeley</city>
        <state>California</state>
        <zip>94710</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Matt Tindall</last_name>
      <phone>415-530-1828</phone>
      <email>matt@flightpath.bio</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>April 6, 2021</study_first_submitted>
  <study_first_submitted_qc>April 6, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">April 8, 2021</study_first_posted>
  <last_update_submitted>April 6, 2021</last_update_submitted>
  <last_update_submitted_qc>April 6, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 8, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lyme Disease</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

